Regeneron Pharmaceuticals (REGN) stock surged 5.05% in intraday trading, defying expectations after reporting first-quarter 2025 earnings that fell short of analyst estimates. The biotechnology company posted adjusted earnings per share of $8.22, missing the Zacks Consensus Estimate of $8.43.
Despite the earnings miss, investor sentiment remains bullish, driven by a flurry of analyst actions. While some firms adjusted their price targets downward, many maintained positive ratings on the stock. Notably, Truist Securities maintained a Buy rating with a price target of $940, Goldman Sachs kept its Buy rating, and Wells Fargo reiterated an Overweight rating. These actions suggest that analysts see strong potential in Regeneron's pipeline and market position, outweighing short-term earnings concerns.
The stock's impressive performance placed Regeneron among the top performers in both the S&P 500 and Nasdaq 100 indices for the day. This surge indicates that investors are focusing on the company's long-term prospects rather than quarterly fluctuations, highlighting the resilience and perceived value of Regeneron in the competitive biotech landscape.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.